Literature DB >> 2129636

Combined gastric and oesophageal 24-hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole.

E C Klinkenberg-Knol1, S G Meuwissen.   

Abstract

Combined oesophageal and gastric 24-hour pH monitoring and oesophageal manometry were performed in 19 patients with resistant reflux oesophagitis after short-term therapy with omeprazole (40 to 60 mg daily) or during maintenance treatment with omeprazole (20 to 80 mg daily). Omeprazole's effects on acidity were analysed as well as any possible influence on oesophageal motility. A pH in the stomach of below 4 was present during considerable periods of time (in 27 of 29 measurements), particularly during the night. As a consequence, pathological gastro-oesophageal reflux occurred, particularly in the supine period. Insufficiency of the lower oesophageal sphincter was present in all but one patient; decreased or virtually absent motility of the oesophagus was found in 63% of the patients. Combined intragastric and intra-oesophageal pH monitoring, with oesophageal manometry, may contribute to the management of patients with reflux disease resistant to treatment with omeprazole. The present study emphasizes the need to individualize therapy in patients with refractory gastrooesophageal reflux disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2129636     DOI: 10.1111/j.1365-2036.1990.tb00495.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  18 in total

1.  Does fasting serum gastrin predict gastric acid suppression in patients on proton-pump inhibitors?

Authors:  E S Bonapace; R S Fisher; H P Parkman
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

2.  Anti-relaxation therapy in GORD.

Authors:  J Tack; D Sifrim
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

3.  H2 antagonist and omeprazole nonresponders.

Authors:  V Savarino; G S Mela; S Vigneri; G Celle
Journal:  Dig Dis Sci       Date:  1991-08       Impact factor: 3.199

4.  The value of ambulatory 24 hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications.

Authors:  Jimmy M Bautista; Wai-Man Wong; Gloria Pulliam; Romeo F Esquivel; Ronnie Fass
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

Review 5.  Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.

Authors:  Katsuhiko Iwakiri; Yoshikazu Kinoshita; Yasuki Habu; Tadayuki Oshima; Noriaki Manabe; Yasuhiro Fujiwara; Akihito Nagahara; Osamu Kawamura; Ryuichi Iwakiri; Soji Ozawa; Kiyoshi Ashida; Shuichi Ohara; Hideyuki Kashiwagi; Kyoichi Adachi; Kazuhide Higuchi; Hiroto Miwa; Kazuma Fujimoto; Motoyasu Kusano; Yoshio Hoshihara; Tatsuyuki Kawano; Ken Haruma; Michio Hongo; Kentaro Sugano; Mamoru Watanabe; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-06-21       Impact factor: 7.527

6.  Proton-pump inhibition and gastric giardiasis: a causal or casual association?

Authors:  H Reynaert; E Fernandes; C Bourgain; L Smekens; G Devis
Journal:  J Gastroenterol       Date:  1995-12       Impact factor: 7.527

Review 7.  Extraoesophageal manifestations of gastro-oesophageal reflux.

Authors:  J Poelmans; J Tack
Journal:  Gut       Date:  2005-10       Impact factor: 23.059

8.  Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis.

Authors:  R H Holloway; J Dent; F Narielvala; A M Mackinnon
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

9.  Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors.

Authors:  G H Koek; D Sifrim; T Lerut; J Janssens; J Tack
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

Review 10.  Pharmacological management of gastro-oesophageal reflux disease.

Authors:  E C Klinkenberg-Knol; H P Festen; S G Meuwissen
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.